Endocrinology and Metabolism

Ju-Young Hong (Hong JY)

1 Article

Clinical Study
Effects of Short-Term Exenatide Treatment on Regional Fat Distribution, Glycated Hemoglobin Levels, and Aortic Pulse Wave Velocity of Obese Type 2 Diabetes Mellitus Patients: Ju-Young Hong, Keun-Young Park, Byung-Joon Kim, Won-Min Hwang, Dong-Ho Kim, Dong-Mee Lim; Endocrinol Metab. 2016;31(1):80-85. Published online March 16, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.1.80

5,018 View
49 Download
26 Web of Science
22 Crossref

Background

Most type 2 diabetes mellitus patients are obese and have obesity related vascular complications. Exenatide treatment is well known for both decreasing glycated hemoglobin levels and reduction in body weight. So, this study aimed to determine the effects of exenatide on body composition, glycated hemoglobin levels, and vascular stiffness in obese type 2 diabetes mellitus patients.

Methods

For 1 month, 32 obese type 2 diabetes mellitus patients were administered 5 µg of exenatide twice daily. The dosage was then increased to 10 µg. Patients' height, body weight, glycated hemoglobin levels, lipid profile, pulse wave velocity (PWV), body mass index, fat mass, and muscle mass were measured by using Inbody at baseline and after 3 months of treatment.

Results

After 3 months of treatment, glycated hemoglobin levels decreased significantly (P=0.007). Triglyceride, total cholesterol, and low density lipoprotein levels decreased, while aspartate aminotransferase and alanine aminotransferase levels were no change. Body weight, and fat mass decreased significantly (P=0.002 and P=0.001, respectively), while interestingly, muscle mass did not decrease (P=0.289). In addition to, Waist-to-hip ratio and aortic PWV decreased significantly (P=0.006 and P=0.001, respectively).

Conclusion

Effects of short term exenatide use in obese type 2 diabetes mellitus with cardiometabolic high risk patients not only reduced body weight without muscle mass loss, body fat mass, and glycated hemoglobin levels but also improved aortic PWV in accordance with waist to hip ratio.

Citations

Citations to this article as recorded by

Adipose tissue inflammation linked to obesity: A review of current understanding, therapies and relevance of phyto-therapeutics
Christiana Eleojo Aruwa, Saheed Sabiu
Heliyon.2024; 10(1): e23114. CrossRef
Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32‐week randomized trial
Liv Vernstrøm, Søren Gullaksen, Steffen S. Sørensen, Kristian L. Funck, Esben Laugesen, Per L. Poulsen
Diabetes, Obesity and Metabolism.2024; 26(5): 1624. CrossRef
Diabetic Sarcopenia. A proposed muscle screening protocol in people with diabetes
Daniel de Luis Román, Juana Carretero Gómez, José Manuel García-Almeida, Fernando Garrachón Vallo, German Guzmán Rolo, Juan José López Gómez, Francisco José Tarazona-Santabalbina, Alejandro Sanz-Paris
Reviews in Endocrine and Metabolic Disorders.2024;[Epub] CrossRef
The Current Landscape of Pharmacotherapies for Sarcopenia
Gulistan Bahat, Serdar Ozkok
Drugs & Aging.2024; 41(2): 83. CrossRef
Vascular Aging: Assessment and Intervention
Ao Li, Jinhua Yan, Ya Zhao, Zhenping Yu, Shane Tian, Abdul Haseeb Khan, Yuanzheng Zhu, Andong Wu, Cuntai Zhang, Xiao-Li Tian
Clinical Interventions in Aging.2023; Volume 18: 1373. CrossRef
The Effect of Additional Treatment with Empagliflozin or Semaglutide on Endothelial Function and Arterial Stiffness in Subjects with Type 1 Diabetes Mellitus—ENDIS Study
Maja Preložnik Navodnik, Andrej Janež, Ivan Žuran
Pharmaceutics.2023; 15(7): 1945. CrossRef
Sarcopenia as a Little-Recognized Comorbidity of Type II Diabetes Mellitus: A Review of the Diagnosis and Treatment
Christian Salom Vendrell, Elisa García Tercero, Juan Bautista Moro Hernández, Bernardo Abel Cedeno-Veloz
Nutrients.2023; 15(19): 4149. CrossRef
Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
Sara Volpe, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Valentina Colaianni, Valentina Lavarra, Domenico Triggiani, Lucilla Crudele, Vincenzo Triggiani, Carlo Sabbà, Giovanni De Pergola, Giuseppina Piazzolla
Frontiers in Endocrinology.2023;[Epub] CrossRef
GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Sydney S. Wilbon, Mikhail G. Kolonin
Cells.2023; 13(1): 65. CrossRef
The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
Yoshinori Ozeki, Takayuki Masaki, Akari Kamata, Shotaro Miyamoto, Yuichi Yoshida, Mitsuhiro Okamoto, Koro Gotoh, Hirotaka Shibata
Medicines.2022; 9(9): 47. CrossRef
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
Juan J. Gorgojo-Martínez, Pedro Mezquita-Raya, Juana Carretero-Gómez, Almudena Castro, Ana Cebrián-Cuenca, Alejandra de Torres-Sánchez, María Dolores García-de-Lucas, Julio Núñez, Juan Carlos Obaya, María José Soler, José Luis Górriz, Miguel Ángel Rubio-H
Journal of Clinical Medicine.2022; 12(1): 145. CrossRef
The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms
Elena Massimino, Anna Izzo, Gabriele Riccardi, Giuseppe Della Pepa
Cells.2021; 10(8): 1958. CrossRef
Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications
Xueli Zhang, Yi Zhao, Shuobing Chen, Hua Shao
Journal of Cachexia, Sarcopenia and Muscle.2021; 12(6): 1368. CrossRef
Effect of glycemic control on markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus: A review
Sofia Antoniou, Katerina K K Naka, Marios Papadakis, Aris Bechlioulis, Agathocles Tsatsoulis, Lampros K Michalis, Stelios Tigas
World Journal of Diabetes.2021; 12(11): 1856. CrossRef
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Jack Alistair Sargeant, Joseph Henson, James Adam King, Thomas Yates, Kamlesh Khunti, Melanie Jane Davies
Endocrinology and Metabolism.2019; 34(3): 247. CrossRef
The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis
Takahiro Yajima, Kumiko Yajima, Hiroshi Takahashi, Keigo Yasuda
Journal of Diabetes and its Complications.2018; 32(8): 759. CrossRef
Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis
Konstantinos Batzias, Alexios S. Antonopoulos, Evangelos Oikonomou, Gerasimos Siasos, Evanthia Bletsa, Panagiota K. Stampouloglou, Chara-Vasiliki Mistakidi, Marina Noutsou, Niki Katsiki, Periklis Karopoulos, Georgios Charalambous, Anastasia Thanopoulou, N
Journal of Diabetes Research.2018; 2018: 1. CrossRef
Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes
N. González, Z. Moreno-Villegas, A. González-Bris, J. Egido, Ó. Lorenzo
Cardiovascular Diabetology.2017;[Epub] CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
Difference in protective effects of GIP and GLP-1 on endothelial cells according to cyclic adenosine monophosphate response
Dong-Mee Lim, Keun-Young Park, Won-Min Hwang, Ju-Young Kim, Byung-Joon Kim
Experimental and Therapeutic Medicine.2017; 13(5): 2558. CrossRef
Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists
Qiuhe Ji
Clinical Therapeutics.2017; 39(6): 1244. CrossRef
Differential Role of Adipose Tissues in Obesity and Related Metabolic and Vascular Complications
Almudena Gómez-Hernández, Nuria Beneit, Sabela Díaz-Castroverde, Óscar Escribano
International Journal of Endocrinology.2016; 2016: 1. CrossRef

Author index